Immunotherapy May Lead to Abnormal Thyroid Function in Patients With Cancer

[D.ap]

"Pembrolizumab, an immune checkpoint inhibitor approved to treat melanoma that has metastasized or cannot be surgically removed, as well as non–small cell lung cancer that has metastasized, is known to sometimes cause immune-related adverse events (AEs), often of the thyroid. A greater understanding of the drug is needed to improve patient care. Delivanis et al aimed to comprehensively characterize pembrolizumab-induced thyroid dysfunction and examine its potential pathophysiology."

http://www.targetedonc.com/conference/a ... ith-cancer